Galmed Pharmaceuticals Reports Strong Cash Position and Expands Therapeutic Focus
I'm PortAI, I can summarize articles.
Galmed Pharmaceuticals Ltd. reported a strong cash position of $19.2 million with minimal debt, and announced an expansion of its therapeutic focus beyond liver disease to include oncology and cardiometabolic indications. The company emphasizes its commitment to value creation through scientific innovation and responsible financial management.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments